Skip Navigation



Japanese Journal of Clinical Oncology Advance Access published online on October 31, 2009
Japanese Journal of Clinical Oncology, doi:10.1093/jjco/hyp124
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Supplementary Data
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Jeung, H.-C.
Right arrow Articles by Chung, H. C.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jeung, H.-C.
Right arrow Articles by Chung, H. C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author (2009). Published by Oxford University Press.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/2.5/uk/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Two Dosages of Oral Fluoropyrimidine S-1 of 35 and 40 mg/m2 bid: Comparison of the Pharmacokinetic Profiles in Korean Patients with Advanced Gastric Cancer

Hei-Cheul Jeung1,2,3, Sun Young Rha1,2,3, Sang Joon Shin1,2,3, Joong Bae Ahn1,2,3, Sung Hoon Noh1,4, Jae Kyung Roh1,2,3 and Hyun Cheol Chung1,2,3

1 Cancer Metastasis Research Center, Yonsei University College of Medicine
2 Department of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine
3 Department of Internal Medicine, Yonsei University College of Medicine
4 Department of Surgery, Yonsei University College of Medicine, Seoul, Korea

For reprints and all correspondence: Hyun Cheol Chung, Department of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, 250 Seongsanno (134, Shinchon-Dong), Seodaemun-Gu, Seoul 120-752, Korea. E-mail: unchung8{at}yuhs.ac

Received May 14, 2009; accepted August 23, 2009

Objective: In this study, we compared the pharmacokinetic profiles of 5-fluorouracil (5-FU), tegafur, 5-chloro-2,4-dihydroxypyridine (CDHP) and potassium oxonate (Oxo) after administration of S-1 at 35 or 40 mg/m2 bid for 28 consecutive days, in Cycles 1 and 3, in patients with advanced gastric cancer.

Methods: Three patients were enrolled for each dosage. S-1 dosage was assigned based on body surface area (BSA), which is different from the Japanese dosing system. The median daily dose per BSA was 76 mg/m2, ranging from 70 to 88 mg/m2.

Results: Plasma levels of 5-FU, tegafur, CDHP and Oxo at 4 h post-dose reached steady-state on day 8. The estimated steady-state level was dependent on S-1 dosage. There were no intercyclic differences of pre-dose and 4 h post-dose levels between Cycles 1 and 3, implying no cumulative effect of S-1 was shown probably due to 2-week drug-resting period. Pharmacokinetic profiles on day 28 were similar to previous Japanese report. Cmax and AUC0–48 h values of each S-1 component increased depending on S-1 dosage. Pharmacokinetic parameters were not correlated with tumor response or toxicity.

Conclusions: We suggest that these pharmacokinetic profiles of Asian population could provide a basis for schedule optimization and for additional studies on interaction with other antitumor drugs.

Key Words: S-1 • gastric cancer • pharmacokinetics • Asian population


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.